- Home
- HRMY vs NFE Comparison
HRMY vs NFE Comparison
Compare HRMY & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- NFE
- Stock Information
- Founded
- HRMY 2017
- NFE 2014
- Country
- HRMY United States
- NFE United States
- Employees
- HRMY N/A
- NFE N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- NFE Oil/Gas Transmission
- Sector
- HRMY Health Care
- NFE Utilities
- Exchange
- HRMY Nasdaq
- NFE Nasdaq
- Market Cap
- HRMY 2.0B
- NFE 641.6M
- IPO Year
- HRMY 2020
- NFE 2019
- Fundamental
- Price
- HRMY $32.16
- NFE $4.05
- Analyst Decision
- HRMY Strong Buy
- NFE Buy
- Analyst Count
- HRMY 9
- NFE 7
- Target Price
- HRMY $54.22
- NFE $12.79
- AVG Volume (30 Days)
- HRMY 609.1K
- NFE 13.7M
- Earning Date
- HRMY 08-05-2025
- NFE 08-08-2025
- Dividend Yield
- HRMY N/A
- NFE N/A
- EPS Growth
- HRMY 13.13
- NFE N/A
- EPS
- HRMY 2.62
- NFE N/A
- Revenue
- HRMY $744,852,000.00
- NFE $2,127,808,000.00
- Revenue This Year
- HRMY $20.10
- NFE $5.86
- Revenue Next Year
- HRMY $18.01
- NFE $21.07
- P/E Ratio
- HRMY $12.27
- NFE N/A
- Revenue Growth
- HRMY 20.62
- NFE N/A
- 52 Week Low
- HRMY $26.47
- NFE $2.01
- 52 Week High
- HRMY $41.61
- NFE $26.22
- Technical
- Relative Strength Index (RSI)
- HRMY 43.25
- NFE 62.53
- Support Level
- HRMY $31.70
- NFE $2.07
- Resistance Level
- HRMY $33.69
- NFE $3.97
- Average True Range (ATR)
- HRMY 0.89
- NFE 0.35
- MACD
- HRMY -0.10
- NFE 0.28
- Stochastic Oscillator
- HRMY 37.30
- NFE 102.81
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.